Silence Therapeutics plc (SLNCF) Q4 2024 Earnings Report

Silence Therapeutics reported QQ4 2024 USD-denominated results with a revenue of $24.33 million and a gross margin of 93.4%, underpinning a robust top line despite a negative operating cadence. The company posted an operating loss of $3.08 million for the quarter, but delivered net income of $14.17 million driven by a sizable non-operating benefit of $26.82 million, resulting in an EPS of $0.31. Net income benefited from non-operating income and tax effects, making the quarter briefly profitable on a GAAP basis despite ongoing R&D intensity and a negative cash flow from operations.

From a liquidity perspective, Silence maintains a substantial cash runway with cash and cash equivalents around $121.33 million and a net cash position around $121.21 million, providing financial flexibility to advance its pipeline. However, operating cash flow remained negative at $24.86 million for QQ4 2024, and free cash flow was negative at approximately $24.92 million, reflecting ongoing investment in R&D and working capital. The balance sheet remains strong with no long-term debt and a current ratio of 11.14, underscoring liquidity readiness to fund late-stage development, potential milestone receipts, and strategic partnerships.

Strategically, Silence continues to push its RNAi platform (mRNAi) through SLN360 and SLN124, supported by collaboration agreements with AstraZeneca, Mallinckrodt, and Hansoh. While the near-term path to sustained profitability depends on operating efficiency and clinical readouts, the quarter reinforces the company’s potential to monetize its collaboration-driven revenue streams and milestone-based payoffs as its clinical programs progress.